🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for DNA Repair Disorder

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer NCT06088030Phase 21 site📍 Guangzhou Yang Li · Tests: Arsenic trioxide Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) NCT05071222Phase 1, Phase 21 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: ARTEGENE drug product Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma NCT06487481Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: Surgical resection, Preoperative RT PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer NCT03740893Phase 26 sites📍 Bournemouth📍 London📍 Manchester Institute of Cancer Research, United Kingdom · Tests: AZD6738, Olaparib, Durvalumab Enhancing the Clinical Management of CMF Through a National Pediatric and Adult Network Based on Biological and Genetic Data NCT07877727n/a4 sites📍 Avellino📍 Genova📍 Naples Istituto Giannina Gaslini Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI NCT04954599Phase 1, Phase 25 sites📍 Brussels📍 Ghent📍 Maastricht Maastricht University Medical Center · Tests: CP-506, Carboplatin, Immune checkpoint inhibitor Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT NCT01962415Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations NCT06334809n/a2 sites📍 Candiolo📍 Orbassano Fondazione del Piemonte per l'Oncologia Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria NCT06834178n/a1 site📍 Graz Vanessa Stadlbauer-Koellner, MD Video Capsule Examination in Patients With Lynch Syndrome NCT06712095NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Video capsule investigation Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome NCT04920149Phase 28 sites📍 Aalborg📍 Hvidovre📍 Gothenburg Ann-Sofie Backman · Tests: Mesalamine, Placebo Clinical and Genetic Studies of Li-Fraumeni Syndrome NCT01443468n/a2 sites📍 Bethesda📍 Bethesda National Cancer Institute (NCI) A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. NCT06898450Phase 1, Phase 222 sites📍 Los Angeles📍 Chicago📍 Louisville Nimbus Wadjet, Inc. · Tests: NDI-219216 Pancreas Registry and High Risk Registry NCT02775461n/a2 sites📍 New York📍 New York Icahn School of Medicine at Mount Sinai Prostate Cancer Genetic Risk Evaluation and Screening Study NCT05129605n/a1 site📍 Boston Massachusetts General Hospital · Tests: Prostate cancer screening Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer NCT07436312NA3 sites📍 Avignon📍 Rennes📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: educational workshop on nutrition + additional intervention on UPF tool and how to use it FITting Non-invasive Tests in Lynch Syndrome Surveillance NCT06898996NA3 sites📍 Chicago📍 Ann Arbor📍 New York University of Chicago · Tests: Fecal immunochemical test Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) NCT07284641Phase 21 site📍 Pittsburgh Paul Szabolcs · Tests: Hematopoietic stem cell transplant (HSCT) Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia NCT05687149n/a1 site📍 Bethesda National Cancer Institute (NCI) Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T) NCT07215416Phase 1, Phase 21 site📍 Boston Timothy Yu · Tests: Antisense oligonucleotide targeting the ATM gene Registry of Subjects at Risk of Pancreatic Cancer NCT04095195n/a4 sites📍 Rozzano📍 Peschiera del Garda📍 Milan Associazione Italiana per lo Studio del Pancreas · Tests: MRCP, Endoultrasonography A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum NCT07811193Phase 2122 sites📍 Tucson📍 Ann Arbor📍 Detroit Vividion Therapeutics, Inc. · Tests: VVD-133214, Pembrolizumab Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia NCT07901959Phase 12 sites📍 Minneapolis📍 New York Rockefeller University · Tests: Metformin, Naproxen Sodium Familial Investigations of Childhood Cancer Predisposition NCT03050268n/a1 site📍 Memphis St. Jude Children's Research Hospital Videocapsule Endoscopy in Lynch Syndrome NCT05704010NA1 site📍 Milan San Raffaele University · Tests: Video capsule endoscopy Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome NCT05847179Phase 21 site📍 Ann Arbor PRG Science & Technology Co., Ltd. · Tests: Progerinin Li-Fraumeni Syndrome/TP53 Biobank NCT04367246n/a2 sites📍 Philadelphia📍 Phildelphia Abramson Cancer Center at Penn Medicine · Tests: No Intervention
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy